Drew Weissman, M.D., Ph.D.

faculty photo
Professor of Medicine
Department: Medicine
Graduate Group Affiliations

Contact information
522 Johnson Pavilion
Philadelphia, PA 19104-6073
Office: (215) 614-0291
Fax: (215) 349-5111
Education:
B.A., M.A. (Biochemistry/Enzymology)
Brandeis University, 1981.
M.D. Ph.D. (Immunology/Microbiology)
Boston University, 1987.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Dr. Weissman's laboratory focuses on the study of RNA and innate immune system biology and the application of these findings to vaccine research and gene therapy. There are three main projects in his laboratory. The first project began through the use of mRNA encoding antigen as a delivery system to load dendritic cells to promote broad immune responses as part of a vaccine. This project has expanded to include basic studies of RNA immunogenicity and translation and the development of applications for gene therapy. The second project develops new HIV envelope immunogens that can induce broad responses and cross-reactive neutralizing antibodies. The third project continues previous studies that identified a protein found on DC, macrophages, and epithelial cells that binds HIV envelope with high affinity. The main focus of this project is testing whether this and related molecules function in vivo to promote HIV genital tract infection.

Selected Publications

Mehta K, Ravimohan S, Pasipanodya JG, Srivastava S, Modongo C, Zetola NM, Weissman D, Ivaturi V, Gumbo T, Bisson GP, Vinnard C: Optimizing ethambutol dosing among HIV/tuberculosis co-infected patients: a population pharmacokinetic modelling and simulation study. J Antimicrob Chemother 74(10): 2994-3002, Oct 2019.

Auld SC, Maenetje P, Ravimohan S, Weissman D, Ncube I, Mlotshwa M, Ratsela N, Chase W, Vangu M-D-T, Wallis R, Churchyard G, Kornfeld H, Bisson GP: Declines in Lung Function After Antiretroviral Therapy Initiation in Adults With Human Immunodeficiency Virus and Tuberculosis: A Potential Manifestation of Respiratory Immune Reconstitution Inflammatory Syndrome. Clin Infect Dis Sep 2019.

Awasthi S, Hook LM, Pardi N, Wang F, Myles A, Cancro MP, Cohen GH, Weissman D, Friedman HM: Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes. Sci Immunol 4(39), Sep 2019.

Pardi N, LaBranche CC, Ferrari G, Cain DW, Tombácz I, Parks RJ, Muramatsu H, Mui BL, Tam YK, Karikó K, Polacino P, Barbosa CJ, Madden TD, Hope MJ, Haynes BF, Montefiori DC, Hu S-L, Weissman D: Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques. Mol Ther Nucleic Acids 15: 36-47, Apr 2019.

Parhiz H, Shuvaev VV, Pardi N, Khoshnejad M, Kiseleva RY, Brenner JS, Uhler T, Tuyishime S, Mui BL, Tam YK, Madden TD, Hope MJ, Weissman D, Muzykantov VR: PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake. J Control Release Page: pii: S0168-3659(18)30586-8, Oct 2018.

Foster JB, Choudhari N, Perazzelli J, Storm J, Hofmann TJ, Jain P, Storm PB, Pardi N, Weissman D, Waanders AJ, Grupp SA, Karikó K, Resnick AC, Barrett DM: Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response. Hum Gene Ther Page: 145, Oct 2018.

Pardi N, Parkhouse K, Kirkpatrick E, McMahon M, Zost SJ, Mui BL, Tam YK, Karikó K, Barbosa CJ, Madden TD, Hope MJ, Krammer F, Hensley SE, Weissman D: Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nat Commun 9(1): 3361, Aug 2018.

Pardi N, Hogan MJ, Naradikian MS, Parkhouse K, Cain DW, Jones L, Moody MA, Verkerke HP, Myles A, Montefiori DC, Lobby JL, Saunders KO, Liao H-X, Korber BT, Sutherland KK, Scearce RM, Hraber PT, Muramatsu H, Ni H, Balikov DA, Lee C, Mui BL, Tam YK, Krammer F, Karikó K, Eisenlohr LC, Madden TD, Hope JM, Lewis MG, Lee KK, Hensley SE, Cancro MP, Haynes BF, Weissman D: Nucleoside-modified mRNA immunization elicits potent T follicular helper cell responses. J Exp Med 215(6): 1571-1588, Jun 2018.

Pardi Nt, Hogan MJ, Naradikian MS, Parkhouse K, Cain DW, Jones L, Moody MA, Verkerke HP, Myles A, Willis E, LaBranche CC, Montefiori DC, Lobby JL, Saunders KO, Liao H-X, Korber BT, Sutherland LL, Scearce RM, Hraber PT, Tombácz I, Muramatsu H, Ni H, Balikov DA, Li C, Mui BL, Tam YK, Krammer F, Karikó K, Polacino P, Eisenlohr LC, Madden TD, Hope MJ, Lewis MG, Lee KK, Hu S-L, Hensley SE, Cancro MP, Haynes BF, Weissman D: Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med 215(6): 1571-1588, Jun 2018.

Ravimohan S, Nfanyana K, Tamuhla N, Tiemessen CT, Weissman D, Bisson GP: Common Variation in Is Associated With Early Death and Elevated Inflammasome Biomarkers Among Advanced HIV/TB Co-infected Patients in Botswana. Open Forum Infect Dis 5(5): ofy075, May 2018.

back to top
Last updated: 10/03/2019
The Trustees of the University of Pennsylvania